Moderna’s RSV Shot Prevents Most Cases in Older People

Moderna COVID-19 vaccines during a vaccination event at the Mexican Consulate of Dallas, on Saturday, March 27, 2021 in Dallas.Moderna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first approval outside Covid-19.

Moderna may apply for approval using a recently acquired voucher for expedited review that could allow the company to launch its vaccine this year, Chief Executive Officer Stephane Bancel said in an interview. While RSV tends to produce mild cold symptoms in many people, it can cause serious complications in seniors, babies and young children. Older patients may develop other lung illnesses on top of RSV, including pneumonia, or suffer worsening of existing conditions such as asthma or congestive heart failure, according to the US Centers for Disease Control and Prevention.

Pfizer’s vaccine prevented 67% of RSV cases overall in older adults and 86% of severe cases in a final-stage trial presented at a conference last fall. GSK’s shot prevented about 83% of RSV cases and 94% of severe RSV cases in older adults. The trials used slightly different case definitions, and the numbers of severe RSV cases were relatively small, making it hard to judge the shots’ relative efficacy.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC. Sure They said the same thing about the Covid vaccine, before it wasn't. Remember? Where have we heard this before?
Source: CNBC - 🏆 12. / 72 Read more »